Immutep’s Lead Candidate Data In Breast Cancer Trial Fails To Lift The Stock
Immutep Limited (NASDAQ:IMMP) has announced final overall survival data (OS) from its Phase 2b AIPAC trial. 227 patients with HER2-negative/HR-positive metastatic…
Immutep Reports Improved And Statistically Significant Survival Benefit For Three Key Patient Groups In Final Phase IIb AIPAC Study Results In Metastatic Breast Cancer
Final Overall Survival (OS) data supports Phase III clinical development of efti in combination with paclitaxel in metastatic breast cancer
OS benefit trend in total population, with median survival benefit of +2.9
Immutep Announced Monday it was Granted Chinese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination With a Chemotherapy Agent
Immutep Limited(NASDAQ: IMMP) is pleased to announcethe grant of a new patent (numberZL 201610221687)entitled "Use of recombinantLAG-3or the derivatives thereof for eliciting a monocyte immune response" by the Chinese Patent Office.
Immutep Filing Shows Co. Received European Medicines Agency Advice For Further Clinical Development Of Efti In Metastatic Breast Cancer, Including Phase 3 Trial
Immutep receives positive EMA scientific advice for
further clinical development of efti in MBC including Phase III
•
Positive feedback for the general clinical development
Immutep To Present Phase II TACTI-002 Data At SITC 2021
Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is
Immutep Reported Late Tuesday that it Received A$3.4M R&D French Tax Incentive
Immutep Limited (NASDAQ: IMMP) is pleased to announce it has received a €2,126,617 (~ A$3,430,952) research and development (R&D) tax incentive payment in cash from the French Government under its Crédit d'Impôt Recherche scheme (CIR).
Immutep to present final Overall Survival data from Phase IIb AIPAC as a Late Breaking Poster Presentation at SITC 2021
Immutep Limited (NASDAQ: IMMP) is pleased to announce it will report final Overall Survival (OS) data from its Phase IIb AIPAC clinical trial evaluating lead product candidate eftilagimod alpha ("efti" or "IMP321") in metastatic breast cancer at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2021.
Evofem, Immutep Shares Spike To Session High Following TipRanks Article ‘2 “Strong Buy” Penny Stocks That Offer Massive Potential Gains’
https://www.tipranks.com/news/article/2-strong-buy-penny-stocks-that-offer-massive-potential-gains/
Immutep Announces Chinese Patent Grant For LAG-3 Antagonist Antibody LAG525
SYDNEY, AUSTRALIA – 27 August 2021 – Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), is pleased to announce the grant of patent no. ZL201580013695.X
The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 26)